Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 10:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,055 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: No Therapy 6 Weeks Clear all
Active, not recruiting Phase 3 Interventional

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874
View directory record Official record
Conditions
Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Procedure · Other · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
895
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 13, 2026, 10:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate Probes in Adolescent Depression

NCT02307617
View directory record Official record
Conditions
Major Depressive Disorder, Major Depressive Disorder, Recurrent, Major Depressive Disorder, Remitted
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
13 Years to 21 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2021 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Women In Steady Exercise Research (WISER) Survivor Trial

NCT01515124
View directory record Official record
Conditions
Lymphedema
Interventions
Exercise Intervention, Weight Loss Intervention
Behavioral
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
Up to 80 Years · Female only
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 1 Interventional Results available

Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty

NCT00750191
View directory record Official record
Conditions
Lower Back Pain
Interventions
The Transdiscal Radiofrequency Annuloplasty
Device
Lead sponsor
Baylis Medical Company
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 13, 2026, 10:53 PM EDT
Terminated Phase 1 Interventional

ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer

NCT02514031
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ARQ-761, Gemcitabine, nab-paclitaxel
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611

NCT02509507
View directory record Official record
Conditions
Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node, Liver Tumors
Interventions
Talimogene Laherparepvec, Pembrolizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
9
States / cities
Scottsdale, Arizona • Santa Monica, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 1 Interventional Results available

A Study of IMC-RON8 in Advanced Solid Tumors

NCT01119456
View directory record Official record
Conditions
Cancer
Interventions
IMC-RON8
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Indianapolis, Indiana • Detroit, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 13, 2026, 10:53 PM EDT
Recruiting Phase 4 Interventional

Post-Operative Thoracolumosacral Orthosis for PJK

NCT06491030
View directory record Official record
Conditions
Proximal Junctional Kyphosis, Adult Spinal Deformity Surgery, Thoracolumbosacral Orthosis
Interventions
Align PJK™ TLSO brace, Standard of Care
Device · Other
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
30 Years to 75 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Carmel, Indiana • Overland Park, Kansas • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

Brief Intervention for Problem Drinking and Partner Violence

NCT01207258
View directory record Official record
Conditions
Domestic Violence, Alcohol Abuse
Interventions
Motivational Enhancement Therapy
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 22, 2016 · Synced Oct 13, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional

Multimodal, Enriched Environment for Rehabilitation in Chronic Traumatic Brain Injury

NCT06734026
View directory record Official record
Conditions
Traumatic Brain Injury (TBI) Patients
Interventions
Cafe Therapy
Behavioral
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Not applicable Interventional Results available

Forearm Rotation Orthosis for Stroke

NCT01987414
View directory record Official record
Conditions
Stroke
Interventions
occupational therapy task-oriented approach, Forearm rotation orthosis, No treatment
Behavioral · Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 13, 2026, 10:53 PM EDT
Terminated Phase 1Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00004093
View directory record Official record
Conditions
Lung Cancer
Interventions
carboplatin, Gemcitabine, paclitaxel, vinorelbine, radiation therapy, Navelbine, Taxol
Drug · Radiation
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Enhancing Self-Efficacy for Caregivers of Family Members With Spinal Cord Injury

NCT02392052
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Reinvention Protocol Participants, Wait List
Behavioral
Lead sponsor
Craig Hospital
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Englewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 13, 2026, 10:53 PM EDT
Active, not recruiting Not applicable Interventional

Texting for Diabetes

NCT03025984
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Texting
Behavioral
Lead sponsor
St. Louis University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

NCT03308942
View directory record Official record
Conditions
Neoplasms
Interventions
Niraparib, Pembrolizumab, TSR-042 (Dostarlimab)
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
16
States / cities
Whittier, Alaska • Port Saint Lucie, Florida • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 13, 2026, 10:53 PM EDT
Recruiting Not applicable Interventional

Radio- KO Radiotherapy for Knee Osteoarthritis Clinical Trial

NCT06887829
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Low dose radiotherapy, Sham comparator
Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 100 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer

NCT00004029
View directory record Official record
Conditions
Prostate Cancer
Interventions
recombinant viral vaccine therapy, sargramostim
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1996
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 13, 2026, 10:53 PM EDT
Withdrawn Phase 2 Interventional

Vedolizumab Post Op Study

NCT02834754
View directory record Official record
Conditions
Crohn's Disease
Interventions
Vedolizumab, placebo
Drug
Lead sponsor
Marc Schwartz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 2 Interventional

Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer

NCT00080808
View directory record Official record
Conditions
Prostate Cancer
Interventions
Alprostadil (E1), Papaverine, Phentolamine mesylate, Sildenafil citrate, conventional surgery
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 65 Years · Male only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 2 Interventional Results available

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

NCT01904604
View directory record Official record
Conditions
Peanut Hypersensitivity, Food Hypersensitivity, Hypersensitivity, Hypersensitivity, Immediate
Interventions
Placebo Viaskin® Patch, Low-dose DBV712 Viaskin® Patch, High-dose DBV712 Viaskin® Patch
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
4 Years to 25 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Denver, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2019 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 4 Interventional

Efficacy of a Novel CCH Protocol for PD Among Prior Non-responders

NCT05108558
View directory record Official record
Conditions
Peyronie's Disease
Interventions
CCH administration, Control - Crossover to CCH, RestoreX
Drug · Device
Lead sponsor
Charitable Union for the Research and Education of Peyronie's Disease
Other
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Orem, Utah
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 2Phase 3 Interventional

Magnesium Chloride Versus Placebo in Patients Who Have Had a Stroke

NCT00933868
View directory record Official record
Conditions
Stroke
Interventions
Magnesium Chloride, Placebo
Drug
Lead sponsor
Relox Medical, LLC
Industry
Eligibility
18 Years to 90 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Grand Rapids, Michigan • Suffern, New York • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2012 · Synced Oct 13, 2026, 10:53 PM EDT
Suspended Phase 1 Interventional

Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

NCT05887882
View directory record Official record
Conditions
Pediatric Brain Tumor, Recurrent Pediatric Brain Tumor, Pediatric Neoplasm
Interventions
Universal Donor (UD) Transforming growth factor beta imprinting (TGFβi) Natural Killer (NK) Cells, Implantation, Magnetic Resonance Imaging (MRI), Quality-of-Life Assessment
Biological · Procedure · Other
Lead sponsor
Sabine Mueller, MD, PhD
Other
Eligibility
1 Year to 38 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 13, 2026, 10:53 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

NCT01580696
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Fallopian Cancer, Peritoneal Cancer
Interventions
E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster, Non-vaccine clinically matched control group, E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster, E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster, E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster
Biological · Other
Lead sponsor
COL George Peoples, MD, FACS
Federal
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Annandale, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 13, 2026, 10:53 PM EDT